Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, today announced that Ryo Kubota, M.D., Ph.D., Acucela's chief executive officer, will present next week at the BIO Business Forum during the 2008 BIO International Convention to be held in San Diego, California from June 17-20.

Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has dosed the first subject in a Phase I trial for its lead compound ACU-02.

Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has filed an investigational new drug (IND) application to conduct a Phase 1 clinical trial for its lead compound ACU-02 with the U.S.

Acucela Inc., a clinical-stage biotechnology company discovering new drug therapies for eye diseases, today presented preclinical data from a study of a blinding eye disease called retinopathy of prematurity (ROP) demonstrating an improvement in retinal abnormalities following treatment with the company's visual cycle modulation compound.

Acucela Inc., a clinical-stage biotechnology company discovering new drug therapies for eye diseases, today announced that data from a preclinical study in retinopathy of prematurity (ROP) will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 27 through May 1 in Fort Lauderdale, Florida.